Category Archives: Immunology

Immunology

Novartis says it overpaid Roche’s Genentech nearly $210M in a licensing dealand it wants its money back – FiercePharma

For years, Novartis said it dutifully shelled out tens of millions to Genentech as part of a patent licensing deal that dated back to 2005. Later, the Swiss pharma discovered it accidentally overpaid by nearly $210 million.

Those are the central arguments in a lawsuit filed by Novartis against its Swiss pharma counterpart seeking $209.5 million.In the suit, whichrecently made its way to California federal court, Novartis says Genentech isn't coughing up the dough.

Novartis claims Genentech was aware, or at least shouldve known, that the company was overpaying the entire time.

The paymentsstemmed from a 2005 licensing agreement Genentech struck with then Chiron Corporation related to its antibody patents. Novartis picked up Chiron a year later and developed several commercial antibody products from the pact, notablyimmunology meds Ilaris and Cosentyx, the suit says.

RELATED:Novartis hits setback in bid to block Regeneron's Eylea prefilled syringe as dual lawsuits drag on

Instead of alerting Novartis of the overpayments, Genentech continued to seek, accept, and retain the funds driven by Ilaris and Cosentyx sales, even though they werent entitled to them, Novartis argued in the filing.

While terms of the initial licensing deal weren't disclosed, Novartis maintains itperformed all or substantially all of its obligations under the deal and later learned of the overpayments after it expired.

Meanwhile, lawyers representing Genentech dismissed Novartis claims in a filing seeking to move the case from state to federal court, arguing the claims fall under federal patent law.

The companies werent immediately available for comment.

RELATED:Novartis' closely watched canakinumab hits a snag in lung cancer. What's next for the anti-inflammatory drug?

Cosentyx, which first launched in 2015, directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.

The treatment has become Novartis largest brand, driving $3.9 billion in sales last year, up 13% compared with the year prior.

Meanwhile, sales of IL-1beta inhibitor Ilaris came in at roughly $873 million, up 30%. Despite efforts to push the medicine, also known ascanakinumab,into fields outside immunology, Novartis has run intomultiple setbacks, including in heart disease, COVID-19 and, most recently, non-small cell lung cancer.

Read the original here:
Novartis says it overpaid Roche's Genentech nearly $210M in a licensing dealand it wants its money back - FiercePharma

Immunology

Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting – Yahoo Finance

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, which is being held virtually from June 8-11, 2021.

Anish Suri, president and chief scientific officer of Cue Biopharma, will discuss preclinical data on CUE-401, the Companys most recent autoimmune drug product candidate. CUE-401, part of the CUE-400 series designed for differentiation and expansion of induced regulatory T cells (iTregs), is a bispecific molecule engineered to deliver the two signals, transforming growth factor beta (TGF-) and interleukin 2 (IL-2), required to induce iTregs in vivo.

Presentation DetailsSession Title: CUE-401: A Novel IL-2/TGF-beta Fusion Protein for the Induction of CD4+ FOXP3+ Regulatory T cellsPresenter: Anish Suri, Ph.D., president and chief scientific officer of Cue BiopharmaSession: Late Breaking Abstracts (Part II)Date and Time: Thursday, June 10, 2021 from 3:45 p.m. 4:00 p.m. PDT

The recorded presentation and poster will be available in the Investor & Media section of the Companys website under Scientific Publications and Presentations, following the presentation at FOCIS 2021 annual meeting.

Presentation data highlights include:

In vivo data show that CUE-401 can effectively induce FOXP3-expressing iTregs from T cells obtained from healthy donors as well as patients suffering from rheumatoid arthritis and inflammatory bowel diseases.

CUE-401 induced iTregs suppressed effector T cell responses.

A single dose of CUE-401 was shown effective at inducing Tregs in mice with active and ongoing autoimmunity.

Dr. Suri commented, We are very excited to share these promising preclinical data demonstrating CUE-401 has the ability to induce and expand regulatory T cells in vitro and in vivo. We believe this is an innovative and potentially effective means of suppressing chronic inflammatory diseases and may provide a more meaningful and lasting benefit to patients suffering from numerous autoimmune diseases, graft versus host disease (GVHD) and even transplant rejection.

About FOCIS Annual Meeting The Federation of Clinical Immunology Societies is a key forum where opinion leaders come together to chart the path to the next major breakthrough in disease therapy. Through FOCIS, researchers and clinicians share knowledge across traditional disease borders, and identify commonalities between treatments and therapies that are life-changing for those impacted by immune-mediated diseases. The FOCIS Annual Meeting educates clinicians, researchers and trainees in the broad discipline of clinical immunology. FOCIS is the worlds leader in immunology education and in training future generations of clinical immunologists. Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2001. After two successful consecutive meetings, FOCIS was incorporated as a 501(c)3 organization in 2003. Today, FOCIS has 58 Member Societies, representing roughly 65,000 clinician scientists.

About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body to transform the treatment of cancer, infectious disease and autoimmune disease. The companys proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform, is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

Story continues

For more information, visit https://www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the companys estimate of the period in which it expects to have cash to fund its operations; the companys belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective engagement of disease-relevant T cells; and the companys business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the companys future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as believe, expect, may, will, should, would, could, seek, intend, plan, goal, project, estimate, anticipate, strategy, future, likely or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the companys strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the companys actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the companys limited operating history, limited cash and a history of losses; the companys ability to achieve profitability; potential setbacks in the companys research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration (FDA) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the companys trials; negative or inconclusive results from the companys clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the companys reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the companys ability to obtain adequate financing to fund its business operations in the future; operations and clinical the companys ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the companys most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.com

Media ContactDarren Opland, Ph.D.LifeSci Communicationsdarren@lifescicomms.com

Originally posted here:
Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting - Yahoo Finance

Immunology

The SSC Platelet Immunology Register of VITT and VIITP: Towards standardization of laboratory and clinical parameters – DocWire News

This article was originally published here

J Thromb Haemost. 2021 Jun 2. doi: 10.1111/jth.15402. Online ahead of print.

ABSTRACT

A severe syndrome of thrombosis and thrombocytopenia has been described in patients vaccinated against severe acute respiratory distress syndrome coronavirus 2 (SARSCoV2) with a chimpanzee adenovirus vector encoding Spike protein (ChAdOx1 nCov-19, AstraZeneca).[1-6] as well as (Ad26.COV2.S, Johnson & Johnson/Janssen).[7] Currently, this novel immune thrombosis syndrome is known as vaccine-induced immune thrombotic thrombocytopenia (VITT) but has been described as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) and thrombotic thrombocytopenia syndrome (TTS) elsewhere.

PMID:34076338 | DOI:10.1111/jth.15402

More:
The SSC Platelet Immunology Register of VITT and VIITP: Towards standardization of laboratory and clinical parameters - DocWire News

Immunology

Global Precision Medicine Market, By Products and Services, – GlobeNewswire

New York, June 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Precision Medicine Market, By Products and Services, By Technology, By Application, By End User, By Region, Competition Forecast & Opportunities, 2026" - https://www.reportlinker.com/p05916716/?utm_source=GNW

Global precision medicine market was valued USD66.85 billion in 2020 and is expected to reach USD125.67 billion, growing at CAGR of 10.65% during the forecast period. Precision medicines are patient specific and vary from individual to individual. Increasing population and rising cancer cases in developing countries like India and China are the major factors propelling the growth of the precision medicine market. However, high price of precision medicines might hamper the growth of the market in the forecast period.

The global precision medicine market is segmented based on products and services, technology, application, end user, and region.The application segment is further divided into oncology, immunology, cardiology, neurology, respiratory and others.

Out of these, oncology held the largest market share in 2020 due to the increasing cases of cancer all over the world.

In terms of regional analysis, market is segregated into Asia-Pacific, North America, South America, Middle East & Africa and Europe.Among these, North America dominated the global precision medicine market until 2020 due to growing adoption of next generation sequencing methods in addition to favorable government policies.

Additionally, Asia-Pacific is anticipated to grow at the fastest CAGR due to the rising cases of cancer and other fatal diseases in the developing economies like India and China.

Major players in the global precision medicine market include IBM Watson Group, Roche Holding AG, Thermo Fischer Scientific Inc., Philips Healthcare Ltd., Illumina Inc., Quest Diagnostics Inc., Qiagen NV, AstraZeneca Plc, Agilent Technologies Inc., Novartis AG, NanoString Technologies Inc., NantHealth Inc., Orion Health Inc., Celcuity Inc., InsightRX Inc., and others. The companies are adopting various organic and inorganic strategies like, product launches, acquisitions and mergers to strengthen their position in the market. On 15th April 2021, Agilent Technologies, Inc. completed the acquisition of Resolution Bioscience, which is a leader in the development and commercialization of next-generation sequencing (NGS) based precision oncology solutions. Resolution Bioscience complements and expands Agilents capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market. Moreover, the addition of Resolution Biosciences liquid biopsy-based diagnostic technologies strengthens Agilents offerings to biopharma and clinical diagnostics customers and boosts growth opportunities in the companys diagnostics and genomics business.

Years considered for this report:

Historical Years: 2016-2019Base Year: 2020Estimated Year: 2021Forecast Period: 20222026

Objective of the Study:

To analyze historical growth in market size of global precision medicine market from FY2016 to FY2020. To estimate and forecast the market size of global precision medicine market from FY2021 to FY2026 and growth rate until FY2026. To classify and forecast global precision medicine market based on products and services, technology, application, end user, and region. To identify drivers and challenges for global precision medicine market. To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global precision medicine market. To conduct pricing analysis for global precision medicine market. To identify and analyze the profile of leading players operating in global precision medicine market.The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of manufacturers across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the manufacturers which could not be identified due to the limitations of secondary research. The analyst examined the manufacturers, distribution channels and presence of all major players across the globe.The analyst calculated the market size of global precision medicine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and Application for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Precision medicine manufacturers, suppliers, distributers and other stakeholders Government bodies such as regulating authorities and policy makers Organizations, forums and alliances related to precision medicine Market research and consulting firmsThe study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global precision medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below: Global Precision Medicine Market, By Products and Services:o Precision Medicine Platformso Precision Medicine Toolso Precision Medicine Services Global Precision Medicine Market, By Technology:o Big Data Analyticso Artificial Intelligenceo Bioinformaticso Whole Genome Sequencingo Companion Diagnosticso Next Generation Sequencing (NGS)o Others Global Precision Medicine Market, By Application:o Oncologyo Immunologyo Cardiologyo Neurologyo Respiratoryo Others Global Precision Medicine Market, By End User:o Pharmaceutical and Biotechnology Companieso Healthcare ITo Diagnostic Companieso Clinical Research Organizationo Research Institutes Global Precision Medicine Market, By Region:o North AmericaUnited StatesCanadaMexicoo EuropeGermanyUnited KingdomFranceItalySpaino Asia-PacificChinaIndiaJapanSouth KoreaAustraliaSingaporeo South AmericaBrazilArgentinaColombiao Middle East & AfricaSouth AfricaSaudi ArabiaUAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global precision medicine market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five)Read the full report: https://www.reportlinker.com/p05916716/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more from the original source:
Global Precision Medicine Market, By Products and Services, - GlobeNewswire

Immunology

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas…

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

PARIS AND CAMBRIDGE, MA April 9, 2021 Sanofi today acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofis research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones. We anticipate that this next generation, off-the-shelf approach has the potential to bring CAR-T cell therapy to a much broader patient population, said Frank Nestle, Global Head of Research and Chief Scientific Officer at Sanofi. We believe that the underlying mRNA targeting platform will create disruptive therapeutic approaches across a variety of oncology and autoimmune conditions.

Tidal Therapeutics utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells. The technology is based on proprietary nanoparticles that deliver mRNA (messages) to reprogram immune cells inside the body. The technology delivers mRNA cargos selectively to designated types of cells in the body, with initial applications targeting specific types of immune cells. The in vivo approach is designed to provide similar efficacy to current ex vivo (outside the body) approaches where immune cells are genetically modified to enhance their therapeutic properties (such as chimeric antigen receptor [CAR]-expressing T-cells), with the potential for improved safety, outpatient dosing, and repeat dosing. Currently, Tidal Therapeutics has ongoing pre-clinical programs including in vivo re-programming of T cells or other types of immune cells for cancer indications.

Teaming up with Sanofi gives us the opportunity to further develop our unique platform and rapidly apply it to ultimately help patients across a range of diseases, said Ulrik Nielsen, President and CEO, Tidal Therapeutics.

About Tidal TherapeuticsTidal Therapeutics is a preclinical biotech company based at LabCentral in Cambridge, MA. The company is focused on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases. The company was seeded by Mission BioCapital, and joined by RA Capital, New Enterprise Associates, the Myeloma Investment Fund, the Multiple Myeloma Research Foundations venture philanthropy, MRL Ventures, and AbbVie Ventures.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Investor Relations Contacts ParisEva Schaefer-JansenArnaud Delepine

Investor Relations Contacts North AmericaFelix LauscherFara BerkowitzSuzanne Greco

IR main line:Tel.: +33 (0)1 53 77 45 45investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact

Read more:
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas...

Immunology

Genomic testing services in pathology & immunology department to be expanded Washington University School of Medicine in St. Louis – Washington…

Visit the News Hub

Changes aimed at improving diagnosis of cancer, inherited diseases

The Department of Pathology & Immunology at Washington University School of Medicine in St. Louis is reorganizing and expanding its genomic medicine testing services to take advantage of advances in genetic and genomic sciences and improve clinical care.

Genetic and genomic testing is driving advances in precision medicine. Such testing provides the data that, when combined with information about disease status and environmental factors, enable doctors to move away from one-size-fits-all treatment plans to personalized therapies tailored to individual needs.

The Department of Pathology & Immunology at Washington University School of Medicine in St. Louis is reorganizing and expanding its genomic medicine testing services to take advantage of advances in genetic and genomic sciences and improve clinical care. Several new tests for cancer and inherited diseases are in the works. The department also is redesigning its website to make it easier for physicians to quickly identify the most appropriate tests for their patients.

As part of the reorganization, the department is establishing two new sections: a molecular oncology section, led by Eric Duncavage, MD, and an inherited diseases section, headed by Jonathan Heusel, MD, PhD.

The School of Medicine has been at the forefront of genetics research for many years, including leadership in whole genome sequencing, saidRichard Cote, MD, the Edward Mallinckrodt Professor and head of the Department of Pathology & Immunology. We have long had a major stake in translating these discoveries into clinically actionable tests to better define prognosis and treatment for a wide variety of diseases. We are delighted that Jon Heusel and Eric Duncavage, widely recognized for their research, are leading the effort to enhance the departments genetic and genomic testing services.

A wide variety of different mutations can give rise to cancer, and the specific mutations carried by a particular tumor affect its susceptibility to a particular treatment. These mutations also can be used to track a tumor during therapy to determine how it is responding to therapy. Clinical cancer genomics aims to use information on tumor mutations to help identify the therapies most likely to benefit the patient and avoid those least likely to help.

Duncavage

Duncavage and his Washington University colleagues recently developed a diagnostic test, ChromoSeq, for blood cancers, based on sequencing the whole genome. This comprehensive analysis has greater sensitivity than traditional testing, providing additional information that could help clinicians assess each patients risk of severe disease and choose the best treatment plan. The test was evaluated in a clinical trial of patients treated at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine. Results of that trial were published in March in The New England Journal of Medicine. ChromoSeq whole genome sequencing for blood cancers will be available as a clinical test through the Department of Pathology & Immunology.

Until recently, we could only analyze a limited set of genes or chromosomes because whole genome sequencing was too expensive for routine clinical use, Duncavage said. But recent advances in sequencing technologies and data analysis techniques have driven down the cost of whole genome sequencing in both time and resources. We showed that the technology could be used for blood cancers, and we are working on applying it to other kinds of cancers.

In addition, Heusel and Duncavage are spearheading an effort to develop tests to identify people with an inherited predisposition to cancer. Most famously, variations in the BRCA1 and BRCA2 genes increase the risk of breast and ovarian cancer, but dozens of other genes have been linked to a range of cancers. In the interest of efficiency, the tests under development are based on sequencing only the 2% of the genome that codes for proteins. This tiny fraction of the genome known as the exome is where nearly all mutations associated with disease risk are found.

Heusel

As chief of the inherited diseases section, Heusel will oversee the development and operation of tests for rare genetic diseases. Some of the people most in need of whole genome testing are babies born with mysterious ailments that appear to have genetic causes. Sequencing an affected newborns entire genome and often the genomes of both parents, too can be the fastest way to find an explanation for a babys condition.

Heusel and colleagues also are working on an improved test for disorders of somatic mosaicism, a group of conditions characterized by mutations in some cells but not others. Patients can have a wide range of symptoms, including overgrowth of one part of the body, such as the hand; skin spots or rashes; and abnormal tangles of blood vessels. The symptoms depend not only on what mutation has occurred but in which cells it has occurred. The researchers are building a faster, cheaper test that will allow more genes and more conditions to be screened.

Genetic testing particularly what we call next-generation sequencing, which involves sequencing dozens or hundreds of genes or whole exomes or whole genomes its transforming medicine, transforming the way we understand the basis of disease, how to diagnose it and how to treat it, Heusel said. What were really trying to do in the department now is make it easier for clinicians to take advantage of all the new genetic and genomic diagnostic tools that are becoming available.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, consistently ranking among the top medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Link:
Genomic testing services in pathology & immunology department to be expanded Washington University School of Medicine in St. Louis - Washington...

Immunology

Assistant/Associate/Full Professor of Veterinary Microbiology and Immunology job with UNITED ARAB EMIRATES UNIVERSITY | 250949 – Times Higher…

Job Description

The United Arab Emirates University's College of Food & Agriculture invites applications for a faculty position in Microbiology with experience in Immunology and the One Health approach for the Department of Veterinary Medicine. Qualified candidates at all levels will be considered at a rank commensurate with academic accomplishments. Candidates are expected to have an understanding of veterinary education that will enable them to teach and coordinate courses in veterinary microbiology (virology, bacteriology, mycology) and immunology at both undergraduate and postgraduate levels as well as advise and mentor students. They should have a proven track record of demonstrable research capability that will enable the candidate to develop and sustain an internally and/or externally funded research program in his/her area of expertise and publish his/her research findings in international peer-reviewed scientific journals. The candidate will contribute to admissions, examining and assessment as well as academic administration in both the Department and the College, and actively promote the growth of the UAE University engaging in interdisciplinary collaboration with other UAEU colleges, e.g. College of Medicine and Health Sciences, College of Science, under the theme of One Health. The application package should include a cover letter, a detailed resume, a brief description of teaching philosophy and current/future research activities, as well as courses taught. English is the language of instruction and communication. Screening of applications will continue until the position is filled.

Minimum Qualification

Applicants must have an earned doctorate in Infectious Diseases, Virology, Bacteriology, Mycology, Immunology or similar field. The ability to teach undergraduate courses is a must. Industrial and professional experience is a plus. Good interpersonal and English oral and written communication skills are required, as is the ability to work with others in a diverse collegial team atmosphere.

Preferred Qualification

Candidates with a degree in veterinary medicine or comparable professional degree with documented accomplishments in teaching, research, and service are preferred. Additional qualifications of innovative and dynamic teaching or other professional skills relevant to a faculty role are desirable. Other evidence of working in One Health-related teaching and/or research especially in the Middle East and North Africa region as well as engagement in international-quality research, with publications and other participation in research activities commensurate with stage of career as well as a track record of securing research funding. Experience with AVMA accreditation requirements, and knowledge of innovative curriculum development and implementation is a plus.

Expected Skills/Rank/Experience

Rank and salary commensurate with accomplishments, expertise and experience. English fluency required. One Health-related teaching and/or research experience. Innovative and dynamic teaching or other professional skills. Record of research grantmaking and publications in international peer-reviewed journals.

Special Instructions to Applicant

Informal enquiries may be made to Prof Arve Lee Willingham (Chair, Department Veterinary Medicine) - awillingham@uaeu.ac.ae

Division College of Food & Agriculture-(CFA)Department Veterinary Medicine - (CFA)Job Close Date open until filledJob Category Academic - Faculty

See more here:
Assistant/Associate/Full Professor of Veterinary Microbiology and Immunology job with UNITED ARAB EMIRATES UNIVERSITY | 250949 - Times Higher...

Immunology

IM Therapeutics Expands Management Team with David Alleva, Ph.D. as VP, Immunology – Business Wire

WOBURN, Mass.--(BUSINESS WIRE)--IM Therapeutics, Inc., a clinical-stage company developing novel, first-in-class therapies targeting human leukocyte antigens (HLAs) to treat autoimmune diseases, announced today that David Alleva, Ph.D., has joined its management team as Vice President, Immunology. Dr. Alleva is an immunologist with deep experience in R&D in autoimmunity and infectious disease spanning 22 years and across early-stage biotech, foundations, and clinical-stage biopharmaceutical organizations.

IM Therapeutics IMT-HALT platform enables the development of oral small molecule drugs to block HLA gene variants as the earliest triggers of autoimmunity. The Companys lead drug candidate, IMT-002, is in a Phase 1b study in type 1 diabetes (T1D) in patients genetically preselected for HLA-DQ8. HLA-DQ8 significantly increases the risk for T1D and is present in 60% of T1D patients.

I am excited to welcome David to our leadership team and impressed by his work in novel approaches in T1D and the autoimmune spectrum, said Nandan Padukone, Ph.D., CEO of IM Therapeutics. David broadens our expertise at a pivotal time as we advance our lead program in T1D through Phase 1 clinical trials and progress our additional programs. Davids advocacy for new ways to treat T1D and his immunotherapy drug development experience will be tremendous assets to the company as we expand our autoimmune-targeted pipeline.

Dr. Alleva has been in senior R&D management positions, most recently at Akston Biosciences where he led immunotherapy development for T1D and a COVID-19 vaccine program. Previously, he led several R&D programs with ADiTx in T1D, managed portfolio programs at JDRF, and helped advance drug development of small-molecules, biologics, and vaccine therapeutics at Emergent BioSolutions, Hollis-Eden Pharmaceuticals, XOMA, and Neurocrine Biosciences.

Dr. Alleva earned a Ph.D. in immunology from the Virginia Polytechnic Institute and State University and performed postdoctoral autoimmune disease research at Boston University Medical Center. He has authored more than 30 peer-reviewed publications, has chaired immunology conferences, and is on the Editorial Board for the Biomedicines MDPI journal.

HLA drug targeting holds great promise and I am very excited by the progress made by IM Therapeutics to tap into this genetically-directed approach for T1D and other autoimmune diseases, said Dr. Alleva. I look forward to joining this dynamic team and bringing forward new personalized medicines to treat the underlying biology of autoimmunity.

About IMT-002

IMT-002, the lead drug candidate of IM Therapeutics, is the first oral genetically targeted drug candidate to be tested in T1D patients, an incurable autoimmune disorder that affects nearly 1.6 million people in the United States. IMT-002 completed a Phase 1a study in 2020 and is currently completing a Phase 1b study in T1D patients preselected for the HLA-DQ8 gene variant. IMT-002 is designed to block HLA-DQ8 to prevent the immune system from attacking insulin-producing beta cells, thereby preserving function in newly diagnosed patients, and is being investigated as a once- or twice-daily drug candidate. Previous studies of a tool drug, L-methyldopa, which is FDA-approved for treating hypertension, in a Phase 1b study, showed effective inhibition of HLA-DQ8 activity in new onset type 1 diabetes patients who had the HLA-DQ8 gene variant. Several in vivo IND-enabling studies indicate that IMT-002, which unlike the tool drug, is not metabolized physiologically, has more potency to block HLA-DQ8 activity and a favorable safety profile.

About IM Therapeutics

IM Therapeutics is a clinical-stage company pioneering personalized, oral medicines that target human leukocyte antigen (HLA) gene variants to treat the root cause of autoimmune diseases. The Companys IMT-HALT platform enables the development of small molecule drugs using in silico docking of millions of compounds into pockets of an HLA variant where self-antigens may bind to trigger autoimmunity. Selected drug hits are then optimized using proprietary structure-based design and activity screening with cell-based assays for specificity of HLA inhibition. Lead drugs developed against an HLA variant have the ability to block a series of self-antigens and therefore the potential to treat a range of autoimmune diseases related to a selected HLA. The Company is building a broad HLA-targeted pipeline in autoimmune disorders including type 1 diabetes, celiac disease, and lupus. Learn more at http://www.IMTherapeutics.com.

See the original post here:
IM Therapeutics Expands Management Team with David Alleva, Ph.D. as VP, Immunology - Business Wire